Genelux (GNLX) Long-Term Investments (2023 - 2024)

Genelux (GNLX) posted quarterly Long-Term Investments of $1.0 million for Q3 2024, down 85.28% quarter-over-quarter from $6.8 million in Q2 2024.

Genelux (GNLX) Long-Term Investments (2023 - 2024) Analysis & Trends

Genelux's Long-Term Investments history runs 2 years deep, the most recent figure standing at $1.0 million for Q3 2024.

In Q3 2024, Long-Term Investments changed N/A year-over-year to $1.0 million; the TTM figure through Sep 2024 stood at $1.0 million (changed N/A YoY), while the FY2023 annual figure was $24000.0, changed N/A from the prior year.
Long-Term Investments for Q3 2024 stood at $1.0 million, down from $6.8 million in the prior quarter.
The five-year high for Long-Term Investments was $6.8 million in Q2 2024, with the low at $24000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	1.77 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.17 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	372.10 Mn
10	Genelux	119.87 Mn	119.87 Mn	-	-

Download Data